Pfizer’s COVID-19 Vaccine 94 Percent Effective in Adults Aged Over 65: Trial

A patient receiving Pfizer's COVID-19 vaccine at the University of Maryland School of Medicine in Baltimore, Md., on May 4, 2020. Courtesy of University of Maryland School of Medicine via AP

One of the leading COVID-19 vaccine candidates was 94 percent effective in adults older than 65, according to new clinical trial results.

New York-based Pfizer and Germany-based BioNTech said Wednesday their phase 3 study of the candidate concluded after meeting all primary endpoints.